This stable HRQL profile for nivolumab aligns with clinical experience in patients with advanced melanoma that PD-1 inhibitors cause fewer severe adverse effects than CTLA-4 blockade, allowing patients to carry on with normal activities to a greater extent [20]. This evidence concerns the gene PDCD1 and melanoma.